Kazia Therapeutics Ltd (KZIA) Stock Analysis and Metrics

Kazia Therapeutics

NASDAQ: KZIA

$12.22 ▼ -0.82 (-6.29%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap19.25 Bn

Div. Yield0.00

Total Debt (Qtr)9.31 Mn

Add ratio to table…

About

Kazia Therapeutics Limited is an emerging oncology-focused biotechnology company engaged in pharmaceutical drug development. The company has a portfolio of development candidates diversified across several distinct technologies with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Its lead program is Paxalisib an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway designed to treat brain cancer. The company is also developing EVT801 a small-molecule selective inhibitor of VEGFR3 targeting lymphangiogenesis and tumor immune micro-environment modulation. Kazia Therapeutics Limited operates primarily in the biotechnology and pharmaceutical industry with a focus on oncology therapeutics.

The company generates revenue through the potential commercialization of its drug candidates Paxalisib and EVT801 upon successful clinical development regulatory approval and market launch. Revenue is expected to come from product sales licensing agreements milestone payments and royalties. Currently the company does not have commercial products on the market and relies on funding from capital raising activities including at-the-market facilities private placements and equity lines of credit to support its research and development operations. The general customer base for future products would include hospitals oncology treatment centers and patients suffering from various cancer indications.

The company operates through the following segments: Paxalisib and EVT801.

• Paxalisib is an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. It is being developed for the treatment of brain cancers including glioblastoma glioma diffuse intrinsic pontine glioma and brain metastases. Paxalisib is orally administered in a 15mg capsule formulation and has received multiple regulatory designations including Orphan Drug Designation Fast Track Designation and Rare Pediatric Disease Designation from the U. S. Food and Drug Administration. The development candidate is the subject of IND 112608 with the FDA and is supported by a robust intellectual property portfolio with patent protection expected to extend through 2036 in key territories.

• EVT801 is a small-molecule selective inhibitor of VEGFR3. It is being developed to target lymphangiogenesis the formation of new lymphatic vessels and to modulate the tumor immune micro-environment. EVT801 was licensed from Evotec SE in April 2021 and is protected by granted or pending composition-of-matter patents in all key territories with exclusivity generally through the early 2030s. The drug is being evaluated in a phase I first-in-human clinical trial for advanced solid tumors with a recommended phase 2 dose of 400mg twice daily when given as a monotherapy. Clinical activity has been observed in High Grade Serous ovarian cancer patients with biomarker evidence supporting VEGFR3 expression and immune micro-environment modulation.

Kazia Therapeutics Limited operates in a highly competitive oncology biotechnology industry where it faces competition from large pharmaceutical companies and other biotechnology firms developing PI3K inhibitors angiogenesis inhibitors and lymphangiogenesis inhibitors. The company's competitive advantages include Paxalisib's unique ability to cross the blood-brain barrier a critical prerequisite for treating brain cancer which distinguishes it from other PI3K inhibitors in clinical development. Additionally EVT801's selective targeting of lymphangiogenesis offers a distinct mechanism of action compared to traditional angiogenesis inhibitors potentially overcoming hypoxia-induced resistance and toxicity issues. The company benefits from a strong intellectual property portfolio multiple FDA regulatory designations and collaborations with leading research institutions.

The company serves patients hospitals and oncology treatment centers. Specific customer names are not disclosed in the filing but the clinical trials are conducted in collaboration with prominent medical institutions including Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Weill Cornell Medicine St Jude Children's Research Hospital University of Sydney Pacific Pediatric Neuro-Oncology Consortium and Australian and New Zealand Children's Haematology/Oncology Group. These partnerships indicate a customer base comprising major cancer research and treatment organizations focused on advancing novel therapies for brain cancer and other solid tumors.

Investment Thesis

▲ Bull case

The early clinical signals from the Phase 1b trial of paxalisib in metastatic triple‑negative breast cancer are increasingly compelling. Three patients have shown objective responses including two partial responses and one confirmed complete metabolic response, which is rare in heavily pre‑treated TNBC. Accompanying biomarker data reveal rapid and sustained reductions in circulating tumor cells and CTC clusters, indicating a mechanistic impact on metastatic potential beyond standard immunotherapy. These observations suggest that paxalisib can reverse immune exhaustion and disrupt EMT‑driven resistance, positioning the combination as a potential backbone for future regimens in difficult‑to‑treat breast cancer. The consistency of tumor shrinkage across multiple metastatic sites reinforces the biological plausibility of the approach and supports deeper investigation in larger cohorts.
The decision to expand enrollment from 12 to 36 patients in the ongoing Phase 1b study reflects confidence in the safety and tolerability profile observed to date. A larger dataset will enable more precise estimation of objective response rate, progression‑free survival and translational biomarker correlations, which are critical for designing a pivotal registrational trial. The expanded trial also facilitates dose optimization and exploration of combinations with pembrolizumab and chemotherapy across multiple cohorts, increasing the chance of identifying an optimal regimen. With additional clinical sites slated for activation by mid‑2026, enrollment targets are likely to be met on schedule, paving the way for topline data readout in early 2027. This progression de‑risks the program and moves the asset closer to a potential partnership or out‑licensing event.
Kazia’s strategic shift toward a three‑layered oncology platform creates multiple value inflection points beyond paxalisib alone. The in‑licensing of the SETDB1‑targeted MSETC program and the advancement of the NDL2 nuclear PD‑L1 degrader address distinct mechanisms of immunotherapy resistance, namely epigenetic silencing and intracellular immune checkpoint accumulation. Preclinical data for NDL2 show tumor growth inhibition of up to 73 % in combination with anti‑PD‑1 in TNBC models and a favorable safety profile, while MSETC aims to restore interferon signaling in resistant tumors. The platform approach allows for rational combination studies, potentially enhancing efficacy of existing checkpoint inhibitors and broadening the addressable market across breast, lung and colorectal cancers. This diversification reduces reliance on a single asset and positions Kazia as an attractive collaborator for larger pharmaceutical firms seeking next‑generation resistance‑overcoming solutions.
The recent $50 million private placement and the subsequent restoration of Nasdaq compliance have materially strengthened the company’s balance sheet and financial flexibility. Stockholders’ equity now comfortably exceeds the $2.5 million minimum requirement, eliminating the threat of delisting and reducing near‑term financing pressure. This capital cushion supports the planned IND‑enabling studies for NDL2 and MSETC, the continued expansion of the paxalisib Phase 1b trial, and preclinical work on EVT801 without immediate need for dilutive financing. A stronger balance sheet also enhances credibility with potential partners and investors, facilitating discussions around milestone‑based collaborations or co‑development agreements. The improved financial standing thus translates into a lower cost of capital and a higher probability of achieving key milestones on time.
Upcoming catalysts over the next 12‑18 months provide multiple near‑term inflection points that are not yet fully reflected in the market’s valuation. Kazia anticipates a clinical and translational update from the paxalisib TNBC Phase 1b trial before the end of Q2 FY26, followed by additional data readouts throughout 2026 and into 2027. The company plans to present preclinical findings on NDL2 at an oncology‑focused scientific meeting in Q2 FY26 and to share further program updates in Q1 FY26. Progress on the SETDB1 platform toward IND‑enabling studies is expected within an 18‑month window, with the combined cost of advancing both NDL2 and MSETC estimated at approximately $6 million. These milestones collectively create a steady stream of news flow that could drive re‑rating if outcomes continue to be favorable.

The early clinical signals from the Phase 1b trial of paxalisib in metastatic triple‑negative breast cancer are increasingly compelling. Three patients have shown objective responses including two partial responses and one confirmed complete metabolic response, which is rare in heavily pre‑treated TNBC. Accompanying biomarker data reveal rapid and sustained reductions in circulating tumor cells and CTC clusters, indicating a mechanistic impact on metastatic potential beyond standard immunotherapy. These observations suggest that paxalisib can reverse immune exhaustion and disrupt EMT‑driven resistance, positioning the combination as a potential backbone for future regimens in difficult‑to‑treat breast cancer. The consistency of tumor shrinkage across multiple metastatic sites reinforces the biological plausibility of the approach and supports deeper investigation in larger cohorts.
The decision to expand enrollment from 12 to 36 patients in the ongoing Phase 1b study reflects confidence in the safety and tolerability profile observed to date. A larger dataset will enable more precise estimation of objective response rate, progression‑free survival and translational biomarker correlations, which are critical for designing a pivotal registrational trial. The expanded trial also facilitates dose optimization and exploration of combinations with pembrolizumab and chemotherapy across multiple cohorts, increasing the chance of identifying an optimal regimen. With additional clinical sites slated for activation by mid‑2026, enrollment targets are likely to be met on schedule, paving the way for topline data readout in early 2027. This progression de‑risks the program and moves the asset closer to a potential partnership or out‑licensing event.
Kazia’s strategic shift toward a three‑layered oncology platform creates multiple value inflection points beyond paxalisib alone. The in‑licensing of the SETDB1‑targeted MSETC program and the advancement of the NDL2 nuclear PD‑L1 degrader address distinct mechanisms of immunotherapy resistance, namely epigenetic silencing and intracellular immune checkpoint accumulation. Preclinical data for NDL2 show tumor growth inhibition of up to 73 % in combination with anti‑PD‑1 in TNBC models and a favorable safety profile, while MSETC aims to restore interferon signaling in resistant tumors. The platform approach allows for rational combination studies, potentially enhancing efficacy of existing checkpoint inhibitors and broadening the addressable market across breast, lung and colorectal cancers. This diversification reduces reliance on a single asset and positions Kazia as an attractive collaborator for larger pharmaceutical firms seeking next‑generation resistance‑overcoming solutions.
The recent $50 million private placement and the subsequent restoration of Nasdaq compliance have materially strengthened the company’s balance sheet and financial flexibility. Stockholders’ equity now comfortably exceeds the $2.5 million minimum requirement, eliminating the threat of delisting and reducing near‑term financing pressure. This capital cushion supports the planned IND‑enabling studies for NDL2 and MSETC, the continued expansion of the paxalisib Phase 1b trial, and preclinical work on EVT801 without immediate need for dilutive financing. A stronger balance sheet also enhances credibility with potential partners and investors, facilitating discussions around milestone‑based collaborations or co‑development agreements. The improved financial standing thus translates into a lower cost of capital and a higher probability of achieving key milestones on time.
Upcoming catalysts over the next 12‑18 months provide multiple near‑term inflection points that are not yet fully reflected in the market’s valuation. Kazia anticipates a clinical and translational update from the paxalisib TNBC Phase 1b trial before the end of Q2 FY26, followed by additional data readouts throughout 2026 and into 2027. The company plans to present preclinical findings on NDL2 at an oncology‑focused scientific meeting in Q2 FY26 and to share further program updates in Q1 FY26. Progress on the SETDB1 platform toward IND‑enabling studies is expected within an 18‑month window, with the combined cost of advancing both NDL2 and MSETC estimated at approximately $6 million. These milestones collectively create a steady stream of news flow that could drive re‑rating if outcomes continue to be favorable.

▼ Bear case

The encouraging clinical data to date are derived from a very small patient sample, which limits the robustness of any efficacy conclusions. Only three patients have exhibited responses in the paxalisib‑pembrolizumab‑chemotherapy cohort, and the complete metabolic response was observed in a patient treated under an expanded access program rather than within the formal trial protocol. Such limited numbers increase the risk that the observed tumor shrinkage and CTC reductions may be anomalous or driven by confounding factors such as prior therapy history or patient‑specific tumor biology. Until larger cohorts demonstrate consistent results, the preliminary nature of the data remains a significant hurdle for regulatory endorsement and partnership interest.
Paxalisib’s development strategy remains heavily reliant on combination with existing checkpoint inhibitors and chemotherapy, which may constrain its differentiation in a crowded marketplace. Numerous pharmaceutical agents targeting the PI3K/AKT/mTOR pathway are already in clinical development for breast cancer, and several have shown limited single‑agent activity, necessitating combination regimens that increase toxicity and complexity. If paxalisib’s benefit is primarily additive rather than synergistic, its commercial appeal could be diminished relative to next‑generation monotherapy agents or novel antibody‑drug conjugates. Moreover, the requirement for PD‑L1‑positive disease (CPS ≥ 10) for the pembrolizumab‑containing cohort narrows the addressable patient pool and may slow enrollment in later‑stage trials.
The preclinical programs NDL2 and MSETC, while scientifically intriguing, are still at an early stage with considerable translational uncertainty. Although NDL2 demonstrated tumor growth inhibition in murine models, the extrapolation of such results to human efficacy is unproven, and the safety profile in humans remains to be established. MSETC’s mechanism targeting a novel SETDB1‑associated nuclear complex lacks validation in clinical specimens, raising concerns about target engagement and potential off‑target effects. The dependency on successful IND‑enabling studies within an 18‑month window introduces execution risk, as any delay or unfavorable toxicology finding would push back clinical entry and increase cash burn.
Despite the recent $50 million financing, Kazia’s cash runway remains constrained given the breadth of its pipeline and the costly nature of oncology drug development. Advancing three parallel programs—paxalisib in Phase 1b/2, NDL2 and MSETC toward IND readiness, plus EVT801—will require substantial investment in clinical manufacturing, trial site fees, biomarker assays and regulatory consulting. The projected $6 million combined cost for NDL2 and MSETC over 18 months, while partially offset by Australian R&D tax incentives, still represents a material outflow. If enrollment in the paxalisib trial encounters delays or if additional dosing cohorts are needed, the company may need to seek further financing sooner than anticipated, potentially leading to shareholder dilution.
Intellectual property considerations and reliance on third‑party collaborators introduce additional layers of risk that are not fully disclosed in the public announcements. The decision to withdraw abstracts from the ASCO 2026 presentation, while explicitly stated as unrelated to safety, raises questions about the sensitivity of the underlying data and the strength of the patent estate protecting paxalisib’s novel mechanisms. Furthermore, the SETDB1 platform was acquired from QIMR Berghofer, making Kazia dependent on that institute for continued scientific input, material transfer agreements and potential milestone obligations that could affect timelines or financial terms. Any disruption in this collaboration or unexpected IP challenges could impede progress and erode investor confidence.

The encouraging clinical data to date are derived from a very small patient sample, which limits the robustness of any efficacy conclusions. Only three patients have exhibited responses in the paxalisib‑pembrolizumab‑chemotherapy cohort, and the complete metabolic response was observed in a patient treated under an expanded access program rather than within the formal trial protocol. Such limited numbers increase the risk that the observed tumor shrinkage and CTC reductions may be anomalous or driven by confounding factors such as prior therapy history or patient‑specific tumor biology. Until larger cohorts demonstrate consistent results, the preliminary nature of the data remains a significant hurdle for regulatory endorsement and partnership interest.
Paxalisib’s development strategy remains heavily reliant on combination with existing checkpoint inhibitors and chemotherapy, which may constrain its differentiation in a crowded marketplace. Numerous pharmaceutical agents targeting the PI3K/AKT/mTOR pathway are already in clinical development for breast cancer, and several have shown limited single‑agent activity, necessitating combination regimens that increase toxicity and complexity. If paxalisib’s benefit is primarily additive rather than synergistic, its commercial appeal could be diminished relative to next‑generation monotherapy agents or novel antibody‑drug conjugates. Moreover, the requirement for PD‑L1‑positive disease (CPS ≥ 10) for the pembrolizumab‑containing cohort narrows the addressable patient pool and may slow enrollment in later‑stage trials.
The preclinical programs NDL2 and MSETC, while scientifically intriguing, are still at an early stage with considerable translational uncertainty. Although NDL2 demonstrated tumor growth inhibition in murine models, the extrapolation of such results to human efficacy is unproven, and the safety profile in humans remains to be established. MSETC’s mechanism targeting a novel SETDB1‑associated nuclear complex lacks validation in clinical specimens, raising concerns about target engagement and potential off‑target effects. The dependency on successful IND‑enabling studies within an 18‑month window introduces execution risk, as any delay or unfavorable toxicology finding would push back clinical entry and increase cash burn.
Despite the recent $50 million financing, Kazia’s cash runway remains constrained given the breadth of its pipeline and the costly nature of oncology drug development. Advancing three parallel programs—paxalisib in Phase 1b/2, NDL2 and MSETC toward IND readiness, plus EVT801—will require substantial investment in clinical manufacturing, trial site fees, biomarker assays and regulatory consulting. The projected $6 million combined cost for NDL2 and MSETC over 18 months, while partially offset by Australian R&D tax incentives, still represents a material outflow. If enrollment in the paxalisib trial encounters delays or if additional dosing cohorts are needed, the company may need to seek further financing sooner than anticipated, potentially leading to shareholder dilution.
Intellectual property considerations and reliance on third‑party collaborators introduce additional layers of risk that are not fully disclosed in the public announcements. The decision to withdraw abstracts from the ASCO 2026 presentation, while explicitly stated as unrelated to safety, raises questions about the sensitivity of the underlying data and the strength of the patent estate protecting paxalisib’s novel mechanisms. Furthermore, the SETDB1 platform was acquired from QIMR Berghofer, making Kazia dependent on that institute for continued scientific input, material transfer agreements and potential milestone obligations that could affect timelines or financial terms. Any disruption in this collaboration or unexpected IP challenges could impede progress and erode investor confidence.

Timing of transfer of goods or services [axis] Breakdown of Revenue (2024)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2024)

Timing of transfer of goods or services [axis] Breakdown of Revenue (2024)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical areas [axis] Breakdown of Revenue (2024)

Timing of transfer of goods or services [axis] Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password